Drug intelligence / Profile preview

APG273

Development stage: Preclinical
Lead developer: Apogee Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

**APG273** is an investigational long-acting combination of zumilokibart, formerly APG777, an anti-interleukin-13 monoclonal antibody, and APG333, an anti-thymic stromal lymphopoietin monoclonal antibody. It is being developed by Apogee Therapeutics as a potential subcutaneous co-formulation intended to provide dual blockade of IL-13 and TSLP, complementary inflammatory drivers of asthma and chronic obstructive pulmonary disease. The program is intended to enable less-frequent dosing for respiratory inflammatory disease. ([apogeetherapeutics.com](https://www.apogeetherapeutics.com/pipeline))

Other names: APG-273APG273APG 273APG333 + APG777APG777 + APG333zumilokibart + APG333

Targets

IL-13 (Interleukin-13)TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on APG273.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APG273.

Explore the full profile